Sign up to save your podcasts
Or
Share Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).
The experts:
- Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis and is provided by touchIME.
For further information visit: www.touchoncology.com/education/impact-of-new-guidelines-in-MDS-AML
View all episodes
By touchpodcasttouchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).
The experts:
- Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis and is provided by touchIME.
For further information visit: www.touchoncology.com/education/impact-of-new-guidelines-in-MDS-AML